FDA approves LED light therapy device from BioPhotas

Biophotonic device developer BioPhotas has received FDA clearance of its Celluma LED light therapy device for six separate utilities: acne treatment, muscle and joint pain, muscle and joint stiffness, muscle spasm, arthritis, and compromised local blood circulation.

Biophotonic device developer BioPhotas (Tustin, CA) has received FDA clearance of its Celluma LED light therapy device for six separate utilities: acne treatment, muscle and joint pain, muscle and joint stiffness, muscle spasm, arthritis, and compromised local blood circulation.

Research funded by the National Aeronautics and Space Administration (NASA; Washington, DC) and the Defense Advanced Research Projects Agency (DARPA; Arlington, VA) using light-emitting diodes (LEDs) or biophotonic therapy has been scientifically proven in recent clinical trials to up-regulate cellular function in the treatment of many common conditions, restoring the body's natural ability to heal itself. Contrasted to many widely accepted therapies where vital tissue is intentionally damaged to create a healing response, using LED light to "re-energize" cellular function in a noninvasive manner allows the body to maintain vitality as nature intended.

The Celluma device uses three distinct wavelengths of LED light energy, modulated with proprietary electronic algorithms to effectively treat a variety of skin, muscle, and joint conditions.

-----

Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Subscribe now to BioOptics World magazine; it's free!

More in Biomedicine